Vietnam’s Ministry of Health has authorised the circulation of a Russian-made cancer medicine named Pembroria. Photo by incentra
The Drug Administration of Vietnam confirmed on November 11 that Pembroria, containing the active ingredient Pembrolizumab at 100 mg/4 ml, has been granted a three-year marketing authorisation. The product is manufactured by Limited Liability “PK-137” in Russia.
Pembroria is formulated as a concentrated solution for infusion, with a shelf life of 24 months from its manufacturing date.
According to the licence holder, Pembrolizumab has more than 14 indications for different cancers, including non-small cell lung cancer, melanoma, colorectal cancer, cervical cancer, renal cell carcinoma and breast cancer.
With demand rising for advanced cancer medicines and better access to modern treatment, the approval of Pembroria in Vietnam is seen as an important development.
